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ABSTRACT 4 
Objectives. Dicarbonyl stress and high concentrations of advanced glycation endproducts (AGEs) 5 
relate to an elevated risk for cardiovascular diseases (CVD). Exercise training lowers the risk for 6 
future CVD. We tested the hypothesis that lifelong endurance athletes have lower dicarbonyl stress 7 
and AGEs compared to sedentary controls and that these differences relate to a better cardiovascular 8 
health profile. Design. Cross-sectional study 9 
Methods. We included 18 lifelong endurance athletes (ATH, 61±7 years) and 18 sedentary controls 10 
(SED, 58±7 years) and measured circulating glyoxal (GO), methylglyoxal (MGO) and 3-11 
deoxyglucosone (3DG) as markers of dicarbonyl stress. Furthermore, we measured serum levels of 12 
protein-bound AGEs N
Ɛ
-(carboxymethyl)lysine (CML), N
Ɛ
-(carboxyethyl)lysine (CEL), 13 
methylglyoxal-derived hydroimidazolone-1 (MG-H1), and pentosidine. Additionally, we measured 14 
cardiorespiratory fitness (VO2peak) and cardiovascular health markers.  15 
Results. ATH had lower concentrations of MGO (196 [180-246] vs. 242 [207-292] nmol/mmol lysine, 16 
P=0.043) and 3DG (927 [868-972] vs. 1061 [982-1114] nmol/mmol lysine, P<0.01), but no GO 17 
compared to SED. ATH demonstrated higher concentrations CML and CEL compared to SED. 18 
Pentosidine did not differ across groups and MG-H1 was significantly lower in ATH compared to 19 
SED. Concentrations of MGO en 3DG were inversely correlated with cardiovascular health markers, 20 
whereas CML and CEL were positively correlated with VO2peak and cardiovascular health markers.  21 
Conclusion. Lifelong exercise training relates to lower dicarbonyl stress (MGO and 3DG) and the 22 
AGE MG-H1. The underlying mechanism and (clinical) relevance of higher CML and CEL 23 
concentrations among lifelong athletes warrants future research, since it conflicts with the idea that 24 
higher AGE concentrations relate to poor cardiovascular health outcomes. 25 
 26 
Key words: oxidative stress; cardiovascular disease; physical activity; exercise physiology  27 
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Introduction 28 
Advanced glycation endproducts (AGEs) are a complex group of modified proteins or lipids that are 29 
formed by a process of non-enzymatically glycation and oxidation. AGEs formation is a slow process 30 
(i.e., weeks to months) and depends on the extent of oxidative stress, degree of hyperglycemia, and 31 
turnover rate of proteins. 
1, 2
 The formation of AGEs is irreversible and AGEs accumulate with 32 
increasing age. Highly reactive dicarbonyls (α-oxoaldehydes) are involved in the fast formation of 33 
AGEs and accumulation of dicarbonyls is known as dicarbonyl stress. 
1, 2
 Dicarbonyls are precursors 34 
for AGEs 
3
 and the most important dicarbonyl marker is the highly reactive methylglyoxal (MGO). 
4
 35 
Dicarbonyl stress and a high concentration of AGEs are linked to the development of cardiovascular 36 
diseases. 
4-6
  37 
 38 
Higher levels of circulating AGEs are also related to higher vascular stiffness. 
7-9
 There are several 39 
mechanisms proposed how AGEs may affect the vascular wall properties, such as binding to receptor 40 
AGEs (RAGEs) and cross-linking matrix proteins in the vessel wall. 
2, 10
 AGE-binding to RAGEs 41 
leads to an upregulation of inflammation and production of reactive oxygen species. 
11, 12
 These 42 
processes augment vascular dysfunction and may promote vascular stiffness. 
11, 12
 Alternatively, AGEs 43 
can also bind to collagen and elastin to form crosslinks with matrix proteins, which promotes vascular 44 
stiffness. 
12
 Strategies to lower the burden of high levels of AGEs may improve cardiovascular health 45 
and need to be explored. 46 
 47 
Regular exercise training is part of a healthy lifestyle and is an effective strategy to reduce the risk for 48 
cardiovascular morbidity and mortality. 
13, 14
 Exercise training attenuates the age-associated decline in 49 
cardiovascular function, 
15, 16
 and improves glucose 
17
 and lipid metabolism. 
18
 Findings from animal 50 
studies suggest that these health benefits of exercise training may relate to a reduction of dicarbonyl 51 
stress and AGEs concentrations. 
19, 20
 Clinical studies linking exercise training with dicarbonyl stress 52 
or AGEs are, however, sparse and conflicting. 
21-23
 A previous study demonstrated that 12 months of 53 
tai chi training for 2 sessions/week significantly reduced serum AGEs concentrations in asymptomatic 54 
middle-aged adults. 
23
 However, another study found no effect on serum AGEs concentrations in 55 
4 
 
middle-aged overweight or obese men after a 3-month aerobic moderate intensity exercise training 56 
program 
21
. Variation in study outcomes may partially relate to the training duration (3 vs. 12 months), 57 
exercise intensity (light vs. moderate), or study population (asymptomatic vs. overweight/obese). 58 
Lifelong endurance athletes may provide better insight to what extent exercise is related to attenuated 59 
AGEs formation.  60 
 61 
Therefore, we tested the hypothesis that lifelong endurance athletes have lower dicarbonyl stress and a 62 
lower concentration of AGEs compared to sedentary controls. Additionally, we explored whether 63 
lower dicarbonyl stress and lower concentration of AGEs relate to a better cardiovascular health 64 
profile.  65 
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Methods 66 
Thirty-six male participants aged >45 years were included and stratified into 2 groups based on their 67 
lifelong exercise patterns: 1) lifelong endurance athletes (ATH, n=18), 2) sedentary controls (SED, 68 
n=18). ATH had to perform ≥20 years of endurance exercise training (e.g., running or cycling) for ≥4 69 
hours/week, whereas SED had to report ≥20 years of habitual physical activity <2 hours/week. Current 70 
smokers, participants with a history of diabetes mellitus or cardiovascular disease, or participants not 71 
able to perform an incremental maximal cycling test were not included in the study. The Local 72 
Committee on Research Involving Human Subjects of the region Arnhem and Nijmegen approved the 73 
study. All participants gave their written informed consent prior to study participation. 74 
 75 
During this cross-sectional study, participants visited our laboratory on 2 separate days. On day 1, 76 
participants were medically screened for eligibility, followed by an incremental maximal cycling test 77 
to determine their physical fitness. On day 2, pulse wave velocity was measured as an index of 78 
vascular stiffness and blood samples were obtained under fasting conditions. Both testing days were 79 
scheduled within a 14-day time-frame, with at least 1 recovery day between measurement day 1 and 2. 80 
 81 
A physician medically screened the participants by taking a detailed medical history, physical 82 
examination, and 12-lead electrocardiogram. After screening, participants performed an incremental 83 
maximal cycling test to determine the cardiorespiratory fitness and peak oxygen uptake (VO2peak, 84 
mLO2/min). The test took place in a temperature-controlled room (18-19˚C) and under the supervision 85 
of a physician. Participants cycled with 60-80 rotations per minute while the workload increased with 86 
20 Watt/min for ATH and 10 Watt/min for CON. Heart rate was continuously measured via a 12 lead-87 
electrocardiogram. Oxygen uptake (VO2 [mL/min]), carbon dioxide output (VCO2 [mL/min]), and 88 
respiratory exchange ratio (RER) were continuously measured via a gas analyser (CPET, Cosmed 89 
v9.1b, Rome, Italy). Lactate concentration (mmol/L) was measured (Lactate Pro™ 2, Arkray, type LT-90 
1730, Kyoto, Japan) via a capillary blood sample taken 1.5 minute after cessation of the exercise test. 91 
The incremental maximal cycling test was considered successful when 2 of the 4 criteria were met: I) 92 
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RER ≥ 1.05, II) achievement of at least 85% of age-predicted maximal heart rate (220 – age), III) 93 
blood lactate ≥ 6.00 mmol/L, or IV) flattening of VO2 uptake curve (≤ 150 mL increase during the last 94 
minute). 
24, 25
 95 
 96 
Lifelong exercise patterns were queried via an exercise history questionnaire, distinguishing 5 age-97 
periods: I) 20-29 years, II) 30-39 years, III) 40-49 years, IV) 50-59 years and V) >60 years. Each 98 
category consisted of 2 queries: 1) type of activity (e.g., running, cycling, etc., or nothing) and 2) 99 
exercise time (hours) per activity per week. Based on the Compendium of Physical Activities 
26
, the 100 
corresponding metabolic equivalent of task (MET) score per exercise activity was determined. 101 
Vigorous exercise activities were defined as a MET score >6. Subsequently, exercise volume (MET-102 
hours/week) was calculated by multiplying exercise time with accompanying MET score. The average 103 
exercise time and dose were calculated over the last 2 decades.  104 
 105 
Before the second testing day, participants were asked to abstain from I) (vigorous) physical activities 106 
for 24 hours, II) caffeine, alcohol, or vitamin supplement intake for at least 18 hours, and III) food 107 
intake for ≥6 hours. Central and peripheral pulse wave velocity was assessed with a three-lead 108 
electrocardiogram and an echo-Doppler ultrasound machine (WakiLoki Doppler, 4 MHz, Atys) at the 109 
left carotid artery, right common femoral artery, and radial artery. The distances between sternal notch 110 
and site of measurement for the carotid artery and between radial artery and common femoral artery 111 
via the umbilicus were measured. 
27
 At least 10 cardiac cycles were recorded for analyses. Based on 112 
the R-R interval and onset of the Doppler waveform, central and peripheral pulse wave velocities were 113 
calculated in Matlab R2014 (The MathWorks Inc., United States). 114 
 115 
Following vascular measurements, a fasting blood sample (8 mL) was obtained from an antecubital 116 
vein for the assessment of concentrations of dicarbonyl stress and AGEs. Additionally, lysine and 117 
traditional cardiovascular risk factors (total-, high-density lipoproteins [HDL]-, low-density 118 
lipoproteins [LDL]-cholesterol, triglycerides, glycated hemoglobin [HbA1C], and glucose) were 119 
determined. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated based on 120 
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glucose and insulin concentrations (IR = (fasting insulin [mU/L] X fasting glucose [mmol/L])/22.5). 
28
 121 
To gain insight in the cardiovascular (risk) profile of ATH and SED, the 10-year CVD risk was 122 
calculated via the Framingham Risk Score (FRS). 
29
  123 
 124 
For measurement of serum levels of diarbonyl components and AGEs, we used ultra-performance 125 
liquid chromatography tandem mass spectrometry (UPLC-MS/MS, Waters, Milford Massachusetts, 126 
USA). UPLC-MS/MS combines liquid chromatography for separation and tandem mass spectrometry 127 
for specific detection. 128 
 129 
Whole blood samples in serum-separating tubes were centrifuged after collection (10 min, 4°C, 3,000 130 
g) and supernatant was stored at –80°C until analysis. Serum levels of dicarbonyl compounds glyoxal 131 
(GO), MGO, and 3-deoxyglucosone (3DG) were analysed following a previously described protocol. 
3
 132 
Briefly, serum samples were deproteinized using perchloric acid and subsequently derivatized with o-133 
phenylenediamine. GO, MGO, and 3DG concentrations were measured using stable isotope-dilution 134 
UPLC-MS/MS (Waters, Milford Massachusetts, USA) with a run-to-run time of 8 min. Intra-run and 135 
inter-run variations were 4.3% and 14.3% for GO, 2.9% and 7.3% for MGO, and 2.4% and 12.0% for 136 
3DG, respectively. 
3
 137 
 138 
Protein-bound serum AGEs N
Ɛ
-(carboxymethyl)lysine (CML), N
Ɛ
-(carboxyethyl)lysine (CEL), 139 
methylglyoxal-derived hydroimidazolone-1 (MG-H1), and lysine were measured with UPLC-MS/MS 140 
(Waters, Milford Massachusetts, USA), as previously described. 
30, 31
 Pentosidine was measured with 141 
high-performance liquid chromatography and fluorescent detection. 
31
 Intra-run and inter-run 142 
variations were 2.8% and 7.1% for CML, 3.7% and 6.4% for CEL, 3.7% and 5.1% for MG-H1, and 143 
2.0% and 3.1% for pentosidine. 
30, 31
 All serum AGEs were adjusted for lysine concentrations as a 144 
marker of total protein concentration. 145 
 146 
Participant characteristics were summarized with means and standard deviations or median and 147 
interquartile range (IQR), when appropriate. Categorical data were analysed using the Fisher's exact 148 
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test. Parameters were checked for normality using a Shapiro-Wilk test and Q-Q plots. Skewed 149 
variables were loge-transformed before statistical analyses were conducted. Differences in participant 150 
characteristics, lifelong exercise patterns, and cardiovascular health markers between ATH and SED 151 
were analysed using an independent Student's t test. As an overall measure of pulse wave velocity, z-152 
scores of central and peripheral pulse wave velocities were averaged. Correlations between markers 153 
for dicarbonyl stress or AGEs and markers for cardiovascular health (BMI, pulse wave velocity, 154 
cardiorespiratory fitness, Framingham risk score, and glucose metabolism) were evaluated using 155 
Spearman’s rank test. All statistical analyses were performed using SPSS 21.0 software (IBM Corp. 156 
Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.). Statistical 157 
significance was assumed at p<0.05 (two-sided).  158 
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Results 159 
Age, height, mean arterial pressure, and smoking history did not differ between groups, but ATH 160 
demonstrated a lower body weight and Body Mass Index compared to SED (Table 1). HbA1c, total 161 
cholesterol, and glucose concentrations did not differ between groups, but ATH demonstrated a higher 162 
HDL cholesterol concentration and lower LDL cholesterol, triglycerides, and HOMA-IR compared to 163 
SED (Table 1). The median time between smoking cessation and study participation was 28 years 164 
(Q25: 12 to Q75: 40) in ATH versus 25 years (Q25: 15 to Q75: 37) in SED (P=0.78). 165 
 166 
ATH showed a significantly higher weekly exercise time and dose compared to SED (Table 1). ATH 167 
mostly performed vigorous-intensity exercise activities (e.g. running or road cycling). We observed a 168 
higher VO2peak in ATH (3544±651 mL/min) compared to SED (2843±519 mL/min, p<0.01). 169 
Likewise, ATH reached a higher power output during the incremental exercise test compared to SED 170 
(p<0.01, Table 1).  171 
 172 
Central pulse wave velocity was significantly lower in ATH (7.0±2.2 m/s) compared to SED (9.2±2.3 173 
m/s, P<0.01). Peripheral pulse wave velocity was significantly lower in ATH (8.1±1.5 m/s) compared 174 
to SED (9.4±1.6 m/s, p=0.017). 175 
 176 
MGO (196 [180-246] vs. 242 [207-292] nmol/mmol lysine, P=0.043) and 3DG (927 [868-972] vs. 177 
1061 [982-1114] nmol/mmol lysine, p<0.01) concentrations were lower in ATH compared to SED 178 
(Figure 1). Glyoxal concentrations did not differ between ATH vs. SED (314 [202-451] vs. 342 [266-179 
388] nmol/mmol lysine, p=0.86, Figure 1).  180 
 181 
CML was significantly higher in ATH (80 [73-89] nmol/mmol lysine) vs. SED (68 [56-76] 182 
nmol/mmol lysine, p<0.01, Figure 2). Similarly, CEL was significantly higher in ATH (35 [28-41] 183 
nmol/mmol lysine) compared to SED (28 [24-34] nmol/mmol lysine, p=0.035). Pentosidine (0.63 184 
[0.59-0.86] vs. 0.56 [0.48-0.67] nmol/mmol lysine, p=0.11) did not differ between groups (Figure 2). 185 
10 
 
MG-H1 concentration was significantly lower in ATH (363 [288-468] nmol/mmol lysine) compared to 186 
SED (460 [340-536] nmol/mmol lysine, p=0.043, Figure 2).  187 
 188 
MGO was positively correlated with BMI, central PWV, and FRS. (Table 2). 3DG was negatively 189 
correlated with VO2peak, but positively correlated with BMI, central and peripheral PWV, FRS, and 190 
glucose (Table 2). GO did not correlate with cardiovascular health parameters (Table 2).  191 
 192 
CML was negatively correlated with BMI and peripheral PWV, but positively correlated with 193 
VO2peak. MG-H1 was negatively correlated with VO2peak (Table 2). Pentosidine was negatively 194 
correlated with peripheral PWV and glucose (Table 2). CEL did not correlate with cardiovascular 195 
health parameters (Table 2).   196 
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Discussion 197 
This study aimed to compare markers of dicarbonyl stress and circulating AGEs between lifelong 198 
endurance athletes and sedentary controls. MGO and 3DG were significantly lower in ATH compared 199 
to SED, and were related to a better cardiovascular health profile. However, we also found that CML 200 
and CEL were significantly higher in ATH compared to SED.  201 
 202 
The benefits of exercise training on cardiovascular health are indisputable 
14-16
, but underlying 203 
mechanisms explaining the lower risk for cardiovascular events in physically active individuals are not 204 
fully understood 
16
. Our results suggest that benefits of exercise training relate to a lower concentration 205 
of MGO and 3DG. These findings are in line with a recent study in rats, which demonstrated that 206 
running exercise was associated with a reduction in dicarbonyl stress 
19
. In general, we found that 207 
markers of dicarbonyl stress showed a moderate, yet significant correlation with cardiovascular health 208 
or metabolic markers. For example, lower concentration MGO and 3DG were correlated to low 209 
Framingham risk score, lower insulin concentration, and better HOMA-IR. Reducing hyperglycaemia 210 
and improving insulin sensitivity may be a first step to reduce accumulation of MGO 
4, 32
 and 3DG 
32
. 211 
High levels of dicarbonyl stress, and especially MGO, increase morbidity risk 
4-6
. MGO is highly 212 
reactive and is mainly catabolized via glyoxalase I of the glyoxalase system. The activity of the 213 
glyoxalase system depends on concentrations of reduced glutathione (GSH) 
4, 33
. Biosynthesis of GSH 214 
is heavily dependent of the antioxidant response element-nuclear respiratory factor (ARE-Nrf) 215 
pathway. Animal and human studies demonstrated that an acute bout of swimming or moderate 216 
intensity endurance exercise training upregulate the ARE-Nrf pathway and GSH biosynthesis. This led 217 
to the hypothesis that exercise training enhances the glyoxalase system and may lower MGO and MG-218 
H1 concentrations. 
34
 Based on our data, it can be speculated that exercise training possibly lowers the 219 
levels of MGO and MG-H1 via an upregulation of the glyoxalase system. Further research is 220 
warranted to explore these pathways. Taken together, our data demonstrated that exercise training is 221 
related to lower levels of MGO, 3DG, and MG-H1. 222 
 223 
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In contrast to our hypothesis, we found that 2 of the 4 AGEs (CML and CEL) were significantly 224 
higher in ATH, whereas MG-H1 was significantly lower in ATH compared to SED. Although MG-H1 225 
is a AGE, it is produced in a much shorter timeframe and is less stable than CML, CEL or pentosidine. 226 
35
 MG-H1 may, therefore, better relate to abnormal accumulation of dicarbonyl stress. 
35
 This could 227 
explain why MG-H1 showed opposite results compared to the other AGEs, since dicarbonyl stress was 228 
lower in ATH compared to SED. 229 
 230 
Previous studies indicated that an increase in AGEs concentration relates to poor health outcomes. 
4-6
 231 
Our findings are contradictory to this concept, as we found an inverse relation between circulating 232 
CML and pulse wave velocity, BMI, and cardiorespiratory fitness. A potential explanation for this 233 
finding could be that exercise enhances collagen turnover rate, which breaks and prevents AGE cross-234 
links in the vessel wall. 
12, 36, 37
 This may contribute to higher levels of circulating AGEs, but this 235 
hypothesis needs to be reinforced with future studies. Alternatively, a recent animal study 236 
demonstrated that a 12-week running exercise training leads to suppressed RAGEs activation in the 237 
aorta of aged rats. 
38
 It could be speculated that attenuated RAGEs activity limits the uptake of AGEs 238 
from the circulation to the surrounding tissue, 
39
 leading to increased levels of circulating AGEs. Thus, 239 
the observation of higher AGEs in lifelong endurance athletes may relate to a higher collagen turnover 240 
and/or suppression of RAGEs due to long-term exercise training. 241 
 242 
Another possible explanation for the higher AGEs concentrations in ATH vs. SED may relate to the 243 
(vigorous) exercise training regimes of our lifelong endurance athletes. Acute exercise induces a 244 
transient increase in oxidative stress, 
40
 which upregulates the formation of AGEs. 
1, 2
 Mice deficient in 245 
NADPH (nicotinamide adenine dinucleotide phosphate) oxidase, a pathway involved in the generation 246 
of reactive oxygen species, showed an impaired CML generation, which suggests that oxidative stress 247 
is a potential stimulus to generate CML. 
41
 Although the sudden increase in oxidative stress is a 248 
necessary stimulus to enhance the anti-oxidative defence mechanism (i.e., glyoxalase system), 
42
 it is 249 
possible that the formation of AGEs is simultaneously upregulated. The positive relation between 250 
exercise dose / time and CML concentrations found in the present study (Table 2) may relate to the 251 
13 
 
effects of sustained exposure to vigorous exercise training. Hence, lifelong and repetitive exposure to 252 
vigorous exercise increases oxidative stress and may boost the accumulation of circulating AGEs in 253 
the blood. Future research is warranted to elucidate the underlying mechanisms and (clinical) impact 254 
of higher AGEs (CML and CEL) concentrations in athletes, as this observation contradicts with the 255 
general believe that high concentrations of circulating AGEs relate to CVD. 256 
 257 
This cross-sectional study is inherent to some limitations. First, the comparison between athletes and 258 
sedentary individuals does not prove that exercise can attenuate the formation of dicarbonyl stress. A 259 
randomized clinical trial would be needed to confirm causation. However, our results indicate that 260 
exercise training is related to lower dicarbonyl stress. Unfortunately, we do not have information about 261 
the dietary habits of the participants. The absorption, bioavailability, and effects of dietary AGEs are 262 
poorly understood in vivo, 
43
 and it could be that diet patterns may contribute to the differences in 263 
AGEs between ATH and SED. AGE-rich food intake has been associated with higher levels of serum 264 
AGEs, whereas an AGE-restricted diet has been associated with lower serum AGEs. 
21
 However, 265 
whether food AGEs influence protein bound AGEs, as measured in this study, is not clear. Free AGEs 266 
may be relatively quickly absorbed, biotransformed, and excreted. On the other hand, high molecule 267 
weight AGEs, such as protein bound AGEs, may not be very extensively absorbed due to insufficient 268 
degradation by gastrointestinal enzymes. 
43
 Further research is warranted to establish a direct relation 269 
between dietary AGEs and protein-bound AGEs. Finally, all the participants of the study were men 270 
and the lifelong athletes performed endurance exercise activities only, which limits the generalizability 271 
of the present study. 272 
 273 
Conclusion 274 
Findings of the present study indicate that lifelong exercise training is associated with lower 275 
dicarbonyl stress (MGO and 3DG), which is related to improved cardiovascular health. Although MG-276 
H1 was lower in lifelong endurance athletes compared to sedentary controls, AGEs concentrations of 277 
CML and CEL were significantly higher in athletes compared to sedentary controls. The underlying 278 
mechanism and (clinical) relevance of higher CML and CEL concentrations among lifelong athletes 279 
14 
 
warrants future research, since it conflicts with the idea that higher AGEs concentrations relate to poor 280 
cardiovascular health. 281 
  282 
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Practical Implications 283 
 Results of our study support the cardiovascular health benefits of lifelong exercise training, as 284 
lifelong endurance athletes demonstrated a better cardiovascular risk profile compared to 285 
sedentary controls. 286 
 Lifelong exercise training is related to lower dicarbonyl stress, as veteran athletes had lower 287 
concentrations of methylglyoxal and 3-deoxyglucosone compared to sedentary controls.  288 
 Lifelong exercise training is related to higher concentrations of advanced glycation 289 
endproducts (N
Ɛ
-(carboxymethyl)lysine and N
Ɛ
-(carboxyethyl)lysine). Although previous 290 
studies indicated that higher concentrations of advanced glycation endproducts were 291 
associated with adverse outcomes, the clinical significance of our findings in a highly active 292 
population is unknown. 293 
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Figure legend 426 
Figure 1. Individual and average values of markers for (A) dicarbonyl stress and (B) advanced 
glycation endproducts in lifelong athletes (circles) and sedentary controls (squares). For dicarbonyl 
markers, GO concentrations did not differ between groups, whereas MGO and 3DG were 
significantly lower in athletes compared to controls. For advanced glycation endproducts, CML and 
CEL concentrations were higher in athletes compared to controls. Concentrations of pentosidine did 
not differ between groups. Concentrations of MG-H1 were lower in athletes compared to controls. 
P-value refers to an independent Student’s t or (¥) Mann-Whitney U test. Group averages are 
presented as median and interquartile range. 
 427 
Table 1. Participants’ characteristics of lifelong endurance athletes (ATH, n=18) and sedentary controls (SED, 
n=18). Data is presented as mean and standard deviation or median and interquartile range (IQR). P-value refers 
to an independent Student’s t test or Mann-Whitney U (*) test. 
 
ATH SED p-value 
n 18 18  
CHARACTERISTICS 
Age (years) 61±7 58±7 0.29 
Height (m) 179±8 181±6 0.31 
Weight (kg) 74±8 87±10 <0.01 
Body Mass Index (kg/m
2
) ¥ 23.6 (21.1-24.9) 26.7 (25.0-27.4) <0.01 
Mean arterial pressure (mmHg) * 98 (90-106) 103 (93-107) 0.70 
 Systolic blood pressure (mmHg) 134±17 137±16 0.53 
 Diastolic blood pressure (mmHg) 84±10 84±10 0.92 
Smoking history (%yes [n]) 10 (56) 15 (83) 0.15 
CARDIOVASCULAR HEALTH PARAMETERS 
Pulse Wave Velocity 
 Central PWV (m/s) 7.0±2.2 9.2±2.3 <0.01 
 Peripheral PWV (m/s) 8.1±1.5 9.4±1.6 0.017 
Framingham Risk Score (%) * 10.1 (7.5-20.3) 16.5 (10.1-19.5) 0.12 
VO2peak (mL/min) 3544±651 2843±519 <0.01 
Fasting blood levels 
 HbA1c (mmol/mol) ¥ 35.5 (34.4-38.3) 35.5 (35.5-38.3) 0.53 
 Cholesterol (mmol/L) 5.4±0.8 5.9±0.9 0.07 
 LDL (mmol/L) 3.3±0.8 4.0±0.8 0.012 
 HDL (mmol/L) 1.8±0.3 1.4±0.3 <0.01 
Triglycerides (mmol/L) * 0.8 (0.7-1.2) 1.3 (1.0-2.4) <0.01 
Glucose (mmol/L) * 4.6 (4.4-5.0) 4.7 (4.4-4.9) 0.66 
Insulin (mU/L) 2.8±1.8 6.8±2.9 <0.01 
HOMA-IR * 0.5 (0.3-0.9) 1.3 (0.8-2.2) <0.01 
LIFELONG EXERCISE PATTERNS 
Exercise time (hours/week) ¥ 7.1 (5.8-11.9) 0.5 (0.0-1.4) <0.01 
Exercise dose (MET-hours/week) ¥ 60 (47-110) 4 (0-12) <0.01 
INCREMENTAL EXERCISE TEST 
Maximal heart rate (beats/min) 165±13 171±15 0.29 
RER (ratio: VCO2 / VO2) * 1.13 (1.06-1.17) 1.08 (1.05-1.14) 0.029 
Lactate (mmol/L) * 11.6 (8.9-12.3) 11.1 (9.4-12.8) 0.77 
Power Output (W) 319±58 209±46 <0.01 
HbA1c: Glycated haemoglobin; HDL: High-density lipoprotein; HOMA-IR: homeostasis model assessment of 
insulin resistance; LDL: low-density lipoprotein; MET: Metabolic Equivalent of Task; PWV: pulse wave 
velocity; RER: respiratory exchange ratio; VO2peak: peak oxygen uptake;  
* Data were loge-transformed before statistical analysis  
¥ non-parametrically tested via Mann-Whitney U 
 
Table_1
Table 2. Spearman’s Rank (ρ) correlations between dicarbonyl stress, advanced glycation endproducts, and 
cardiovascular health parameters 
 Dicarbonyl stress  Advanced glycation endproducts 
 
GO MGO 3DG 
 
CML CEL Pentosidine MG-H1 
CARDIOVASCULAR HEALTH MARKERS 
BMI 0.02 0.35* 0.40*  -0.53** -0.13 -0.31 0.19 
Average PWV 0.12 0.35* 0.55**  -0.54** 0.10 -0.31 0.04 
 Central PWV 0.24 0.51** 0.46**  -0.30 0.07 -0.10 0.03 
 Peripheral PWV -0.05 0.10 0.44**  -0.58** 0.11 -0.43* 0.02 
VO2peak (mL/min) 0.01 -0.32 -0.47**  0.34* 0.33 0.18 -0.55** 
FRS 0.24 0.52** 0.43**  -0.23 -0.06 -0.09 0.11 
Glucose -0.19 0.15 0.46**  -0.13 0.13 -0.41* -0.09 
Insulin 0.04 0.36* 0.44**  -0.36* -0.24 -0.12 0.35* 
HOMA-IR -0.01 0.34 0.49**  -0.36* -0.21 -0.16 0.33 
LIFELONG EXERCISE PATTERNS 
Exercise time  -0.04 -0.34* -0.53**  0.46** 0.32 0.28 -0.36* 
Exercise dose  -0.04 -0.34* -0.53**  0.45** 0.36* 0.30 -0.37* 
3DG: 3-deoxyglucosone; CEL: NƐ-(carboxyethyl)lysine; CML: NƐ-(carboxymethyl)lysine; FRS: Framingham risk 
score; GO: glyoxal; HOMA-IR: homeostasis model assessment of insulin resistance; MG-H1: Methylglyoxal-derived 
hydroimidazolone-1; MGO: methylglyoxal; VO2peak: peak oxygen uptake (cardiorespiratory fitness); Average PWV: 
average pulse wave velocity, the average of the z-scores of central and peripheral PWV; 
Correlation is significant at *0.05 or **0.01 level (two-sided). 
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